Download
journal.pone.0274043.pdf 711,86KB
WeightNameValue
1000 Titel
  • “All of the things to everyone everywhere”: A mixed methods analysis of community perspectives on equitable access to monoclonal antibody treatment for COVID-19
1000 Autor/in
  1. Kwan, Bethany |
  2. Sobczak, Chelsea |
  3. Gorman, Carol |
  4. Roberts, Samantha |
  5. Owen, Vanessa |
  6. Wynia, Matthew K. |
  7. Ginde, Adit A. |
  8. Pena-Jackson, Griselda |
  9. Ziegler, Owen |
  10. Ross DeCamp, Lisa |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-11-23
1000 Erschienen in
1000 Quellenangabe
  • 17(11):e0274043
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0274043 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683597/ |
1000 Ergänzendes Material
  • https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0274043#sec020 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Neutralizing monoclonal antibody (mAb) treatment for COVID-19 prevents hospitalization and death but is underused, especially in racial/ethnic minority and rural populations. Reasons for underuse and inequity may include community member lack of awareness or healthcare access barriers, among others. This study assessed mAbs community awareness and opportunities for improving equitable mAb access. METHODS: A concurrent mixed methods study including surveys and focus groups with adults with high-risk conditions or their proxy decision-makers. Surveys and focus group guides addressed diffusion of innovation theory factors. Descriptive statistics and Fisher’s exact method was used to report and compare survey findings by race and ethnicity. Rapid qualitative methods were used for focus group analysis. RESULTS Surveys from 515 individuals (460 English, 54 Spanish, 1 Amharic), and 8 focus groups (6 English, 2 Spanish) with 69 participants, completed June 2021 to January 2022. Most survey respondents (75%) had heard little or nothing about mAbs, but 95% would consider getting mAb treatment. Hispanic/Latino and Non-Hispanic People of Color (POC) reported less awareness, greater concern about intravenous infusions, and less trust in mAb safety and effectiveness than White, Non-Hispanic respondents. Focus group themes included little awareness but high interest in mAb treatment and concerns about cost and access barriers such as lacking established sources of care and travel from rural communities. Focus groups revealed preferences for broad-reaching but tailored messaging strategies using multiple media and trusted community leaders. CONCLUSIONS: Despite unfamiliarity with mAb treatment, most respondents were open to receiving mAbs or recommending mAbs to others. While mAb messaging should have broad reach “to everyone everywhere,” racial and geographic disparities in awareness and trust about mAbs underscore need for tailored messaging to promote equitable access. Care processes should address patient-level barriers like transportation, insurance, or primary care access. COVID-19 treatment dissemination strategies should promote health equity.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Surveys
lokal Vaccines
lokal Monoclonal antibodies
lokal Virus testing
lokal Drug therapy
lokal Antibody therapy
lokal Health care providers
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-4013-5618|https://frl.publisso.de/adhoc/uri/U29iY3phaywgQ2hlbHNlYQ==|https://frl.publisso.de/adhoc/uri/R29ybWFuLCBDYXJvbA==|https://frl.publisso.de/adhoc/uri/Um9iZXJ0cywgU2FtYW50aGE=|https://frl.publisso.de/adhoc/uri/T3dlbiwgVmFuZXNzYQ==|https://frl.publisso.de/adhoc/uri/V3luaWEsIE1hdHRoZXcgSy4=|https://frl.publisso.de/adhoc/uri/R2luZGUsIEFkaXQgQS4=|https://frl.publisso.de/adhoc/uri/UGVuYS1KYWNrc29uLCBHcmlzZWxkYQ==|https://frl.publisso.de/adhoc/uri/WmllZ2xlciwgT3dlbg==|https://frl.publisso.de/adhoc/uri/Um9zcyBEZUNhbXAsIExpc2E=
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. National Institutes of Health |
  2. National Center for Advancing Translational Sciences |
1000 Fördernummer
  1. -
  2. UL1-TR002535-03;3UL1TR002535-03S3
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer National Center for Advancing Translational Sciences |
    1000 Förderprogramm -
    1000 Fördernummer UL1-TR002535-03;3UL1TR002535-03S3
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6452880.rdf
1000 Erstellt am 2023-06-22T07:32:20.357+0200
1000 Erstellt von 337
1000 beschreibt frl:6452880
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-08-01T10:22:42.778+0200
1000 Objekt bearb. Tue Aug 01 10:22:15 CEST 2023
1000 Vgl. frl:6452880
1000 Oai Id
  1. oai:frl.publisso.de:frl:6452880 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source